Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria
Open Access
- 27 February 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 334
Abstract
Bepotastine, a second-generation antihistamine for allergic rhinitis and urticaria, is widely used in all age groups but lacks appropriate dosing guidelines for pediatric patients, leading to off-label prescriptions. We conducted this study to propose an optimal dosing regimen for pediatric patients based on population pharmacokinetic (popPK) and physiologically based pharmacokinetic (PBPK) models using data from two previous trials. A popPK model was built using NONMEM software. A one-compartment model with first-order absorption and absorption lag time described our data well, with body weight incorporated as the only covariate. A PBPK model was developed using PK-Sim software version 10, and the model well predicted the drug concentrations obtained from pediatric patients. Furthermore, the final PBPK model showed good concordance with the known properties of bepotastine. Appropriate pediatric doses for different weight and age groups were proposed based on the simulations. Discrepancies in recommended doses from the two models were likely due to the incorporation of age-dependent physiological factors in the PBPK model. In conclusion, our study is the first to suggest an optimal oral dosing regimen of bepotastine in pediatric patients using both approaches. This is expected to foster safer and more productive use of the drug.Keywords
Funding Information
- Ministry of Food and Drug Safety (18183MFDS492, HI23C121600)
- Korea Health Industry Development Institute (KHIDI) (18183MFDS492, HI23C121600)
This publication has 30 references indexed in Scilit:
- Predictive Performance of Physiology‐Based Pharmacokinetic Dose Estimates for Pediatric Trials: Evaluation With 10 Bayer Small‐Molecule Compounds in ChildrenThe Journal of Clinical Pharmacology, 2021
- Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary taleJournal of Pharmacokinetics and Pharmacodynamics, 2018
- Second generation H1 - antihistamines interaction with food and alcohol—A systematic reviewBiomedicine & Pharmacotherapy, 2017
- Applied Concepts in PBPK Modeling: How to Build a PBPK/PD ModelCPT: Pharmacometrics & Systems Pharmacology, 2016
- Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing RegimensCPT: Pharmacometrics & Systems Pharmacology, 2015
- Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy SubjectsClinical Drug Investigation, 2013
- A Pharmacokinetic Standard for Babies and AdultsJournal of Pharmaceutical Sciences, 2013
- Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations2012
- Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutionsJournal of Pharmaceutical Sciences, 2011
- Pharmacokinetics and dosage adjustment in patients with hepatic dysfunctionEuropean Journal of Clinical Pharmacology, 2008